Uterine sarcoma with posterior reversible encephalopathy syndrome associated with pazopanib

What is known and objective Our objective is to report on a case of posterior reversible encephalopathy syndrome associated with pazopanib. Case description A 64-year-old patient with uterine sarcoma developed PRES 3 days after pazopanib was initiated. After the discontinuation of pazopanib, the symptoms of PRES improved. What is new and conclusion The first report worldwide to describe a patient with uterine sarcoma experiencing PRES caused by pazopanib. Patients with uterine sarcoma may experience PRES, even in the early phase of pazopanib therapy.